GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update : vimarsana.com

Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 millionTopline interim...

Related Keywords

Zurich , Züsz , Switzerland , Paris , France General , France , United States , Cambridge , Cambridgeshire , United Kingdom , Sakina Sayah Jeanne , Tom Huijbers , Pascal Prigent , Sandra Silvestri , Steven Hildemann , Drug Administration , Hepatology Communications , Regulatory Agency , Euronext , Transition Services Agreement , Madrigal Pharmaceuticals , Public Accounting Firm , Partb Transition Services Agreement , European Medicine Agency , School Of Engineering , Research Translational Science , Nasdaq , Committee As Executive Vice , Research As , Exchange Commission , Board Of Directors The Company , Uncertainties Of The Company , Company Annual Shareholder Meeting , Primary Biliary , Acute On Chronic Liver , Biliary Cholangitis , Marketing Authorization Application , New England Journal , Priority Review , New Drug Application , United Kingdom Medicines , Licensing Agreement , Chronic Liver Failure , Seal Rock Therapeutics , Investigational New Drug , Hepatology Reports , Annual Shareholder Meeting , Executive Vice President Research , Translational Science , Executive Vice President Regulatory , Consolidated Financial Statements , Independent Registered Public Accounting Firm , Urea Cycle Disorders , Organic Acidemias , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Registration Document , Half Year Business , Financial Report , Drug User Fee , Full Year , Provides Corporate , Markets ,